Skip to main content
HeartCited

Berberine 관련 대사증후군(심혈관 측면)

B 근거 적어도 하나의 무작위 시험이 이를 지지하며, 대체로 일관된 결과를 보입니다.

Improves multiple metabolic parameters: glucose, lipids, BMI, waist circumference. AMPK activation addresses insulin resistance — the core driver of metabolic syndrome.

<\/script>\n
`; }, get iframeSnippet() { const domain = 'heartcited.com'; const params = 'ingredient\u003Dberberine\u0026condition\u003Dmetabolic\u002Dsyndrome\u002Dcardiovascular'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    


    
    

      Widget powered by
      .
      Free, no account required.
    

  




    








    

        

            B

        

        

            
결론

            
            
Improves multiple metabolic parameters: glucose, lipids, BMI, waist circumference. AMPK activation addresses insulin resistance — the core driver of metabolic syndrome.

            
            
        

    










    

  
Key Study Findings





    

        
        

            

                
                    Other
                
                
                
                6 weeks
                
                
            

            
                Berberine alleviates metabolic dysfunction-associated steatohepatitis by enhancing the abundance of Akkermansia muciniphila.
            
            

                
                Dose: None
                
                
                vs: MCD diet MASH model; Abx + FMT experiments
                
                
                Outcome: Hepatic/colonic inflammation, Akkermansia abundance
                
                
                효과: None
                
                
                None
                
            

            
            
대상 집단: MCD diet-induced MASH C57BL/6J male mice

            
        

        
        

            

                
                    Other
                
                
                
                
            

            
                The combination of berberine and evodiamine ameliorates high-fat diet-induced non-alcoholic fatty liver disease associated with …
            
            

                
                Dose: None
                
                
                vs: None
                
                
                Outcome: None
                
                
                효과: None
                
                
                None
                
            

            
            
대상 집단: None

            
        

        
        

            

                
                    Systematic Review
                
                
                n=61
                
                
                
            

            
                Berberine for prevention of dementia associated with diabetes and its comorbidities: A systematic review.
            
            

                
                Dose: None
                
                
                vs: None
                
                
                Outcome: None
                
                
                효과: None
                
                
                None
                
            

            
            
대상 집단: Alzheimer's disease patients

            
        

        
    







    
    

        
        

            

  
Key Statistics





            


    

        
20

        
연구

    

    

        
2500

        
참여자

    

    

        
            
            ↑
            
        
        
Positive

    

    

        B

        
등급

    




        


        
        
        

            

  
Referenced Papers





            

                
                

                    

                        
                            Berberine alleviates metabolic dysfunction-associated steatohepatitis by enhancing the abundance of Akkermansia muciniphila.
                        
                        
                            
                                Other
                            
                            
                            
                        
                    

                    

                        The Journal of …
                        2025
                        
                        1 인용
                        
                    

                

                
                

                    

                        
                            The combination of berberine and evodiamine ameliorates high-fat diet-induced non-alcoholic fatty liver disease associated with modulation of gut microbiota in …
                        
                        
                            
                                Other
                            
                            
                            
                        
                    

                    

                        Brazilian journal of …
                        2022
                        
                        12 인용
                        
                    

                

                
                

                    

                        
                            Berberine for prevention of dementia associated with diabetes and its comorbidities: A systematic review.
                        
                        
                            
                                Systematic Review
                            
                            
                            
                        
                    

                    

                        Journal of integrative …
                        2020
                        
                        33 인용
                        
                    

                

                
            

        

        

        
        
        

            

  
Dosage & Usage





            
mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units


            
            

                
일반적으로 사용되는 용량

                

                    
                    

                        
general:

                        
500-1,500 mg/day divided TID

                    

                    
                    

                        
lipidsupport:

                        
500 mg TID with meals

                    

                    
                

                
                

                    상한량: Not formally established; GI side effects limit doses >1,500 mg/day
                

                
            

            

            
            

                
연구에서 사용된 용량

                

                    

                        
                            

                                용량
                                기간
                                효과
                                N
                            

                        
                        
                            
                            

                                None
                                6 weeks
                                
                                    
                                    Positive
                                    
                                
                                --
                            

                            
                            

                                None
                                --
                                
                                    
                                    Mixed
                                    
                                
                                --
                            

                            
                            

                                None
                                --
                                
                                    
                                    Positive
                                    
                                
                                61
                            

                            
                        
                    

                

            

            

            
            

                권장 복용 시간: With meals, divided TID for sustained plasma levels; short half-life
            

            
        

        

        
        
        

            

  
Safety & Side Effects





            

                
                

                    
보고된 부작용

                    
    
                        
                        
  • 
                            ⚠
                            Diarrhea (most common, usually resolves in 2 weeks)
                        
    • 
                        
                        
  • 
                            ⚠
                            Constipation
                        
    • 
                        
                        
  • 
                            ⚠
                            Flatulence
                        
    • 
                        
                        
  • 
                            ⚠
                            Abdominal pain
                        
    • 
                        
                        
  • 
                            ⚠
                            May lower blood sugar (monitor in diabetics)
                        
    • 
                        
                    

                

                

                
                

                    
알려진 상호작용

                    
    
                        
                        
  • 
                            ●
                            Metformin (additive blood sugar lowering; may increase metformin levels)
                        
    • 
                        
                        
  • 
                            ●
                            CYP2D6 and CYP3A4 substrates (berberine is a CYP inhibitor)
                        
    • 
                        
                        
  • 
                            ●
                            Cyclosporine (may increase blood levels)
                        
    • 
                        
                        
  • 
                            ●
                            Macrolide antibiotics (may prolong QT interval)
                        
    • 
                        
                        
  • 
                            ●
                            Statins (complementary mechanism; monitor for additive effects)
                        
    • 
                        
                    

                

                

                
                

                    

                        일일 최대 섭취 허용량: Not formally established; GI side effects limit doses >1,500 mg/day
                    

                

                
            

            

                건강기능식품을 복용하기 전에 반드시 의료 전문가와 상담하십시오.
            

        

        

        
        
        

            

  
Frequently Asked Questions





            




    
    

        
            Does Berberine help with 대사증후군(심혈관 측면)?
            
        
        

            Based on 20 studies with 2,500 participants, there is moderate evidence from clinical studies that Berberine may support 대사증후군(심혈관 측면) management. Our evidence grade is B (Good Evidence).
        

    

    
    

        
            How much Berberine should I take for 대사증후군(심혈관 측면)?
            
        
        

            Studies have used various dosages. A commonly studied range is 500-1,500 mg/day divided TID. Always consult your healthcare provider before starting any supplement regimen.
        

    

    
    

        
            Are there side effects of Berberine?
            
        
        

            Reported side effects may include Diarrhea (most common, usually resolves in 2 weeks), Constipation, Flatulence, Abdominal pain. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
        

    

    
    

        
            How strong is the evidence for Berberine and 대사증후군(심혈관 측면)?
            
        
        

            We rate the evidence as Grade B (Good Evidence). This rating is based on 20 peer-reviewed studies with 2,500 total participants. The overall direction of effect is positive.
        

    

    




        

        

        
        
        

            

  




            

                

                
                

                    
Berberine 다른 건강 상태에 대한 근거

                    

                        
                        
                            고지혈증(이상지질혈증)
                            B

                        
                        
                        
                            고혈압
                            C

                        
                        
                    

                

                
            

        

        

    


    
    






  
References

  
    
    
    
  1. 
      [1]
      Jiahui Xu et al..
      J Nutr Biochem.
      2025.
      Berberine alleviates metabolic dysfunction-associated steatohepatitis by enhancing the abundance of Akkermansia muciniphila.
      doi:10.1016/j.jnutbio.2025.110069
      PubMed
    
    2. 
    
    
  2. 
      [2]
      Yufan Dai et al..
      Braz J Med Biol Res.
      2022.
      The combination of berberine and evodiamine ameliorates high-fat diet-induced non-alcoholic fatty liver disease associated with modulation of gut microbiota in …
      doi:10.1590/1414-431X2022e12096
      PubMed
    
    3. 
    
    
  3. 
      [3]
      Noriko Shinjyo et al..
      J Integr Med.
      2020.
      Berberine for prevention of dementia associated with diabetes and its comorbidities: A systematic review.
      doi:10.1016/j.joim.2020.01.004
      PubMed
    
    4. 
    
  















    

        FDA 면책 조항:
        이 내용은 미국 식품의약국(FDA)의 평가를 받지 않았습니다. 이 웹사이트의 제품 및 정보는 질병의 진단, 치료, 완치 또는 예방을 목적으로 하지 않습니다. 제시된 근거 등급은 발표된 동료 심사 연구에 대한 우리의 분석에 기반하며, 의학적 조언을 구성하지 않습니다. 건강기능식품 복용을 시작하기 전에 반드시 의료 전문가와 상담하십시오.